Date: 2014-01-13
Type of information: Distribution agreement
Compound: point of care diagnostic tests (IB10, PT10 and HC10 equipment together with associated reagents)
Company: Diaxonhit (France) Samsung (South Korea)
Therapeutic area:
Type agreement: distribution
Action mechanism:
Disease:
Details: * On January 13, 2014, Diaxonhit has announced that the company strengthens its offering in the field of immunoassay and point of care (“POC”) tests for public and private clinical laboratories as well as emergency services. InGen, its commercialization affiliate, has signed a distribution agreement with Samsung Group (In Vitro Diagnostic Department of Samsung Electronics France). The agreement covers the marketing of IB10, PT10 and HC10 equipment together with associated reagents, in France and its overseas territories.
Diaxonhit is already active in the field of immunoassays and in emergency units with its proprietary Tetanus Quick Stick test (\"TQS®\"), and through the distribution of Quidel Corporation’s SOFIA systems.
With this new agreement, the Group will offer to 800 hospital laboratories and 600 emergency services, three new innovative POC diagnostic instruments. These automates and related reagents cover cardiac markers (IB10), biochemistry (PT10) and blood counts (HC10). With these instruments and associated reagents, grouped within the LABGEO product line, it is possible to obtain faster analytical results from a simple blood sample mixed with an anticoagulant (heparinized whole blood) in a centrifugation-free process. The IB10 and PT10 operate using all-inone disposables. They help ensure optimal traceability of all performed tests and can manage directly up to 5000 patient records. This range of instruments and reagents are CE-IVD marked, and can be included in an ISO 22870 quality system (POC analyses standard).
Financial terms:
Latest news:
